Notícias

Drugmaker expands genetic medicine push with Ascidian partnership targeting rare kidney diseases.

Eli Lilly (NYSE:LLY) reported Phase 3 LIBRETTO-432 data showing Retevmo (selpercatinib) cut the risk of recurrence or death in early-stage RET fusion-positive non-small cell lung cancer. The results position Retevmo as a potential new adjuvant standard of care for this genetically defined group of lung cancer patients. Separately, Lilly released encouraging first-in-human data for VERVE-102, a gene-editing therapy targeting cardiovascular disease. Eli Lilly enters this news cycle with a...

Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

Eli Lilly and Co. announced separate licensing and research agreements with South Korea-based Hanmi Pharm and China-based Haisco Pharmaceutical Group, expanding its access to new drug candidates and discovery programs. The deals come as investors also evaluate positive Phase 3...

SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.

Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity. According to a Polymarket post on X, Coinbase (NASDAQ:COIN) founder Brian Armstrong’s longevity startup NewLimit has tripled in value to $3.1 billion. That post sparked a viral reply thread from podcast host Mgoes (@m_goes_distance), cataloging billionaire and ... Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry

Eli Lilly (NYSE:LLY) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion. Mounjaro and Zepbound combined for $12.8 billion in Q1 alone. Yet shares are up just 1.11% year to date, sitting at $1,082.92. Can LLY reach $1,500 a share by 2028? Why Lilly Shares Have ... Where Will Eli Lilly Stock be In 2028?

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.

The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA

Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.

Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it’s prescribed, not faddish. So this is the next 90-million-customer industry, sitting in plain sight while everyone ... 5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

Apple stock, Alphabet, ASML and more ride the market's power trend. But they also offer lessons on when and how to buy stocks.

The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Memory chipmaker Micron Technology leapfrogged South Korean rival SK Hynix to become the 12th most-valuable company in the world, in a rally that has more than tripled the stock this year. Shares jumped another 7.5% Monday to $1,044, lifting the...

The UAE launch marks the start of Novo's global rollout, with additional launches planned later this year.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.

Eli Lilly's pipeline is an embarrassment of riches.

It is finally bouncing back after several challenging years.

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

An upcoming trial result could change how investors think about the weight-loss drug market.

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy now for long term growth. Eli Lilly and Company (NYSE:LLY) announced on May 28 that its full obesity medicine portfolio would now be covered by all three of the largest pharmacy benefit managers in the nation. This considerably expands the number of Americans […]

Big Tech has been driving the stock market rally, but these healthcare, financial, and utilities ETFs are starting to look good.

PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.

Deals total $2.5 trillion so far this year. Casinos and home builders are hot right now, but watch for more action in biotechs and financials.

CVS Caremark has moved to cover Eli Lilly's full obesity drug portfolio, including the newly approved oral therapy Foundayo. The decision aligns CVS Caremark with other major U.S. pharmacy benefit managers that now include Eli Lilly's obesity medicines on their formularies. Coverage spans both Foundayo and injectable products such as Zepbound, widening insurance access across key distribution channels. Eli Lilly (NYSE:LLY) has become a central player in obesity care, with a portfolio that...